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and those without night pain (WN-group) and core temperature
of theirs was compared. Statistical analysis was performed using
repeated measures ANOVA and p value less than 0.05 was
considered as statistically signiﬁcant.
Results: Core temperature of both the knee and the sternum
decreased at around 5 am according to circadian rhythm.
Core temperature of the knee was signiﬁcantly lower than that of
the sternum in KOA. On the other hand, such difference was not
seen in control knees.
Core temperature of the knee between N-group and WN-group
was not different.
Conclusions: We revealed the lower core temperature of the
knee in end-stage KOA. This indicated existence of blood ﬂow
disturbance in OA knees. Our data supports decreased bone
perfusion in KOA exhibited with perfusion MRI. Elevated bone
marrow pressure measured with invasive technique was also
reported as one possible mechanisms of KOA pain and it might
related to blood ﬂow disturbance, though inconsistent results was
reported about bone marrow pressure.
In the present study, we ﬁrstly reported blood ﬂow disturbance in
KOA by measuring core temperature. We only dealt end-stage OA
patients in this study, but this non-invasive method might be useful
in monitoring KOA status.
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DURATION OF A SINGLE INTRAARTICULAR INJECTION OF
GEL-200 AND SAFETY OF RE-TREATMENT OF GEL-200, A
NEW CROSS-LINKED FORMULATION OF HYALURONIC
ACID [HA] IN THE TREATMENT OF SYMPTOMATIC
OSTEOARTHRITIS [OA] OF THE KNEE
H.S. Baraf1, V. Strand2, H. Hosokawa3, O. Akahane3, S. Lim3,
M. Yaguchi3
1The Ctr. For Rheumatology and Bone Res., Wheaton, MD; 2Div.
of Immunology/Rheumatology, Stanford Univ., Palo Alto, CA;
3Seikagaku Corp., Tokyo, Japan
Purpose: This was a randomized controlled trial (RCT) with exten-
sion and open-label re-treatment phases to determine if single or
repeated intra-articular injections of Gel-200 are safe and effective
in subjects with symptomatic knee osteoarthritis.
Methods: Subjects completing Week 13 in SI-6606/01 RCT were
offered enrollment in extension phase, evaluating durability of
responses relative to initial baseline for up to 13 weeks. If and
when subjects qualiﬁed for re-treatment based on WOMAC pain
subscore ≥40 mm in treated knee, they received a single injection
of Gel-200 at Week R0 (open-label baseline). Survival analyses
were conducted in Kaplan-Meier and Cox proportional hazard
models to compare time to re-treatment eligibility using 2 different
pre-speciﬁed endpoints: (A) WOMAC pain subscore ≥40 mm; and
(B) WOMAC Pain ≥40 mm and improvement from baseline <20
mm.
Results: Of 350 completing SI-6606/01; 258 subjects entered
extension: 199 subjects were re-treated with Gel-200; 74 ana-
lyzed for continued effectiveness. Kaplan-Meier estimates showed
a statistically signiﬁcant advantage for Gel-200 in both Endpoints
A (p=0.049) and B (p=0.034). [Table] Median times to re-treatment
eligibility were 6.3 weeks for subjects initially receiving Gel-200
compared with 3.7 weeks for PBS by (A), and 13.1 vs 6.0 weeks by
Endpoint (B). In Cox proportional hazard models, Gel-200 showed
statistically signiﬁcant advantages in durability of response, using
treatment, age, and baseline WOMAC pain subscore as covariates
for Endpoints A (p=0.019) and B (p=0.027). All subjects receiv-
ing open label Gel-200 demonstrated improvement from Week
R0 baseline in WOMAC scores (pain, stiffness, function, total),
global assessments (subject, physician) (P<0.0001); incidence of
adverse events [AEs] within 24 hours of injection were comparable
to those observed in initial RCT. There were no allergic reactions
or unanticipated device-related AE. Serious AE occurred in 6
subjects, none related to the study injection.
Survival Analysis - Kaplan-Meier Estimates
Weeks post injection Endpoint A Endpoint B
in the SI-6606/01 study (p=0.049) (p=0.034)
Gel-200 PBS Gel-200 PBS
(N=247) (N=128) (N=247) (N=128)
Week 1 1.000 1.000 1.000 1.000
Week 3 0.952 0.941 0.961 0.942
Week 6 0.522 0.390 0.616 0.500
Week 9 0.473 0.355 0.560 0.441
Week 13 0.419 0.346 0.514 0.406
Week 16 (Week 3 in Extension phase) 0.292 0.264 0.387 0.342
Week 19 (Week 6 in Extension phase) 0.292 0.264 0.387 0.342
Week 22 (Week 9 in Extension phase) 0.280 0.264 0.375 0.342
Week 26 (Week 13 in Extension phase) 0.280 0.237 0.375 0.317
Conclusions: Together, these data support the efﬁcacy and dura-
bility of response of a single intraarticular injection of Gel-200 over
13 weeks as treatment for knee osteoarthritis. This study also
demonstrated that repeat treatment of Gel-200 was well tolerated.
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Purpose: To assess the long-term safety and effectiveness of
tapentadol extended release (ER), a novel centrally acting anal-
gesic in development for the management of moderate to severe
chronic pain, over 1 year of treatment in patients with chronic low
back or osteoarthritis pain.
Methods: Patients were randomized 4:1 to receive controlled,
adjustable, oral bid doses of tapentadol ER 100-250 mg or oxy-
codone HCl controlled release (CR) 20-50 mg. In order to establish
an optimal therapeutic dose, deﬁned as a dose providing a bal-
ance of efﬁcacy and tolerability, patients could titrate their doses in
increments of 50-mg bid tapentadol ER or 10-mg bid oxycodone
HCl CR during a 51-week maintenance period. Safety was as-
sessed for all patients who received at least 1 dose of study
medication.
Results: Patients received tapentadol ER (n = 894) or oxycodone
CR (n = 224). The mean (standard deviation) and median most
frequently used daily doses were 352.2 (132.43) mg and 400
mg with tapentadol ER and 56.8 (30.07) mg and 40 mg with
oxycodone HCl CR. Patients who received tapentadol ER and
oxycodone CR took the most frequently used dose for a median
duration of 133.5 and 45.0 consecutive days, respectively. Patients
in the oxycodone CR group discontinued treatment earlier than
patients in the tapentadol ER group; in the ﬁrst 4 weeks of
the study, approximately 40% of patients in the oxycodone CR
group discontinued treatment compared with approximately 20%
of patients in the tapentadol ER group. The percentage of patients
who discontinued because of adverse events (AEs) during the
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15-week treatment period was lower in the tapentadol ER group
(22.7%) than in the oxycodone CR group (36.8%).
Conclusions: Treatment over 1 year with tapentadol ER (100-250
mg bid) for the relief of moderate to severe chronic pain was
associated with a longer period of dose stability than oxycodone
HCl CR (20-50 mg bid). This may have been because of a
numerically lower rate of discontinuations early in the study and
a numerically lower rate of overall AE-related discontinuations
throughout the trial in the tapentadol ER group compared with the
oxycodone CR group.
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THE EFFECTS OF SHOCKWAVE ON BONE HEALING AND
SYSTEMIC CONCENTRATIONS OF NITRIC OXIDE (NO),
TGF-β1, VEGF AND BMP-2 IN LONG BONE NON-UNIONS
C.-J. Wang
Chang Gung Mem. Hosp. -Kaohsiung Med. Ctr., Chang Gung
Univ. Coll. of Med., Taiwan, Kaohsiung Hsien, Taiwan
Purpose: We hypothesized that the elevations of systemic con-
centrations of nitric oxide level and osteogenic factors may reﬂect
a local stimulation of shockwave in bone healing in long bone
non-unions. This study investigated the effects of extracorporeal
shockwave treatment (ESWT) on bone healing and the systemic
concentrations of NO (nitric oxide) level, TGF-β1 (transforming
growth factor-β1), VEGF (vessel endothelial growth factor) and
BMP-2 (bone morphogenic protein-2) in long bone non-unions.
Methods: Non-union was deﬁned when the fracture failed to heal
in six months from the initial treatment. The inclusion criteria
comprised of patients with non-unions of diaphyseal fractures of
femur and tibia. Patients must be skeletally matured and are
mentally competent and agree to the follow-up examinations. The
exclusion criteria included patients with underlying pathological
fracture, fracture in the epiphyseal region or active bone infection,
patients with fracture near major neurovascular structures such as
spine and skull or chest wall, patients with cardiac pacemaker and
cardiac arrhythmia, patients receiving immunosuppressive drugs
or anti-coagulation therapy and pregnancy.
Forty-two patients with 42 established non-unions of the femur
and tibia were enrolled in this study. Each long bone non-union
was treated with 6000 impulses of shockwave at 28 Kv (=0.62
mJ/mm2 energy ﬂux density) in a single session. Ten milliliters of
peripheral blood were obtained for measurements of serum NO
level and osteogenic growth factors including TGF-β1, VEGF and
BMP-2; serum levels of calcium, alkaline phosphatase, calcitonin
and parathyroid hormone before treatment and at 1 day, 1, 3 and 6
months after treatment. The evaluations for bone healing included
clinical assessments and serial radiographic examinations.
Results: At six months, bony union was radiographically conﬁrmed
in 78.6%, and persistent non-union in 21.4%. Patients with bony
union showed signiﬁcantly higher serum NO level, TGF-β1, VEGF
and BMP-2 at one month after treatment as compared to patients
with persistent non-union (Table 1).
Table 1 The results of NO Level, TGF-β1, VEGF and BMP-2 at one month after
treatment
NO and osteogenic Normal Control Union Non-union P-value-3
markers (N=16) (N=33) (N=9)
NO 53.2±6.4 99.0±52.3 68.1±26.9
P-value-2 0.003 0.228 0.017
TGF-β1 42742±4000 60986±13661 49337±8132
P-value-2 0.002 0.306 0.034
VEGF 383±351 532.3±318.3 290.7±190.2
P-value-2 0.02 0.495 0.028
BMP-2 72.4±6.4 86.4±29.5 68.8±5.5
P-value-2 0.035 0.266 0.003
Conclusions: Shockwave-promoted bone healing was associated
with signiﬁcant increases in serum NO level and osteogenic growth
factors. The elevations of systemic concentration of NO level and
the osteogenic factors may reﬂect a local stimulation of shock-
wave in bone healing in long bone non-unions. Clinical relevancy:
The measurements of serum NO level and the osteogenic fac-
tors may be used as the predictors in bone healing in long bone
fractures.
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FACTORS RELATED TO DISEASE SPECIFIC DISABILITY
AND GENERAL HEALTH PHYSICAL DISABILITY IN
PATIENTS WITH KNEE OSTEOARTHRITIS
K.K. Briggs, L.M. Matheny, J. Steadman
Steadman Hawkins Res. Fndn., Vail, CO
Purpose: Many studies have shown relationships between BMI
and knee osteoarthritis. The purpose of this study was to deter-
mine other factors that may be related to knee osteoarthritis. This
will be measured as disease speciﬁc disability and general health
physical disability.
Methods: Demographic, objective and radiographic data were
collected on 325 patients who presented to a referral clinic for
treatment of osteoarthritis of the knee. Data collected included
gender, age, BMI, Kellgren Lawrence Grade (KL), shift in mechan-
ical axis of the knee, knee extension and ﬂexion, WOMAC, and the
SF-12 physical component and mental component. The WOMAC
score was converted to a percentage score with 100% equal to
perfect WOMAC and 0% equal to worst WOMAC. The WOMAC
was considered the disease speciﬁc measure of disability and the
physical component score (PCS) of the SF-12 was considered the
general health measure of disability.
Results: There were 168 males and 157 females. The average
age was 61 years (range 40 to 87). The average self-reported
BMI was 26 kg/mm2 (range 18 to 42). 186 were considered
overweight (BMI ≥25 kg/mm2) and 142 were considered normal
(<25 kg/mm2). The average knee extension was 3 degrees (range
-10 to 43 degrees) and the average ﬂexion was 124 degrees
(range 25 to 165). There were 31% grade 4 KL, 40% grade 3,
and 29% grade 2. The average shift in mechanical axis was 27%
(range 0 to 50).
Gender was not associated with WOMAC, however, males did
have a higher PCS (40 vs 38; p=0.019). Grade II KL patients had
signiﬁcantly lower BMI (25 vs 27; p=0.009) and higher WOMAC
score (68% vs 63%; p=0.049). Of the grade II KL patients, 50%
were overweight, of the grade III KL patients, 59% were over-
weight, and of the grade IV KL patients 69% were considered
overweight (p=0.041).
In this patient population, an increase in mechanical axis shift was
correlated to a decrease in ﬂexion (r=-0.16; p=0.006). An increase
in mechanical axis shift (r=-0.137; p=0.031), loss of extension (r=-
0.178; p=0.014), higher BMI (r=-0.264; p=0.001) and an increase
in age (r=-0.190; p=0.002) were all correlated with an decrease in
PCS. An extension loss (r=-0.219; p=0.001) and a increase in BMI
(r=-0.214; p=0.001) were correlated with an decreased WOMAC.
One independent predictor of WOMAC was identiﬁed. It was loss
of extension (r2=0.24; p=0.008). Independent predictors of PCS
included age (p=0.002), WOMAC (p=0.0001) and BMI (r2=0.43;
p=0.001).
Conclusions: Loss of extension predicted disease speciﬁc dis-
ability (WOMAC). For general health disability, predictors included
age, BMI, and WOMAC. General health was more affected by
demographic variables, while disease speciﬁc was related to knee
